Page last updated: 2024-08-24

imiquimod and Neoplasms

imiquimod has been researched along with Neoplasms in 49 studies

Research

Studies (49)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (2.04)	18.2507
2000's	12 (24.49)	29.6817
2010's	16 (32.65)	24.3611
2020's	20 (40.82)	2.80

Authors

Authors	Studies
Cao, Y; Chen, Q; Li, L; Liu, S; Liu, W; Ran, H; Shang, T; Tan, M; Wang, Z; Xie, Z; Zhang, L; Zhang, W	1
Bai, J; Chen, J; Deng, S; Guan, Y; Niu, C; Qiao, Y; Wang, W; Wang, X; Yang, N; Zhu, S	1
Dong, WF; Li, L; Mei, Q; Miao, P; Wang, P; Yue, J	1
Cao, J; He, L; Huang, P; Luo, J; Shi, Z; Sun, Y; Wang, X; Zeng, Y; Zhang, T	1
Chen, L; He, L; Huang, P; Luo, J; Shi, Z; Wang, X; Yao, J; Zeng, Y; Zhang, T	1
Chen, X; Chen, Y; Huang, Y; Jia, Z; Liu, J; Liu, Y; Wen, Y; Yuan, X	1
Bhatta, R; Bo, Y; Han, J; Liu, Y; Wang, H	1
Choi, E; Goforth, A; Landry, M; Neufeld, M; Pennock, N; Sun, C; Walker, J; Weinfurter, K	1
Liu, Z; Qu, X; Ren, J; Sun, M; Wu, L; Yang, J	1
Chang, R; Chu, X; Feng, C; Fu, R; Jia, D; Li, G; Li, J; Wang, R; Yan, H; Zhang, J	1
An, Y; Bai, S; Dai, Q; Ge, J; Liu, G; Lu, Z; Wang, Z; Wu, S; Xu, D	1
He, W; Liu, X; Qing, X; Wei, P; Yang, Z; Yu, Y; Zhang, G; Zhang, J; Zhao, M; Zhou, M; Zhu, S; Zhu, X	1
Hu, X; Ouyang, L; Wang, J; Wang, Y; Zhang, J	1
Li, W; Lin, B; Lv, R; Ning, P; Tao, X; Wang, Y; Yuan, Y	1
Chen, M; Chong, L; He, C; Li, J; Song, X; Wang, D; Xing, M; Zhang, C; Zhang, X	1
Karthikeyan, L; Rithisa, B; Vivek, R	1
Arnold-Schild, D; Bartneck, J; Grabbe, S; Hartmann, AK; Klein, M; Langguth, P; Meiser, SL; Muth, S; Pielenhofer, J; Probst, HC; Radsak, MP; Schild, H; Stassen, M	1
Gou, M; Huang, M; Huang, Y; Kang, T; Li, Y; Liu, J; Wang, S; Wang, Y; Wei, X; Xiong, M; Yang, L; Zhu, J	1
Han, D; Huynh, M; Hwang, ST; Jena, PK; Sheng, L; Shi, Z; Wan, YY; Wu, X; Yu, S; Zhou, Y	1
Chen, WR; Qu, J; Saunders, D; Smith, N; Song, J; Towner, RA; Wang, L; Wang, M; Zhou, B; Zhou, F	1
Abelson, KSP; Kanui, TI; Kisipan, ML; Ojoo, RO	1
Arens, R; Doorduijn, EM; Maas, S; Ossendorp, F; Salvatori, DC; Silvestri, S; Sluijter, M; van der Burg, SH; van Hall, T	1
Alaverdyan, K; Chai, S; Fuchs, E; Gomez, NC; Kulukian, A; Larsen, SB; Naik, S; Polak, L; Sendoel, A; Yuan, S	1
Arnaiz, B; Bocanegra Gondan, AI; Cobaleda-Siles, BM; Escors, D; García-Granda, MJ; Gato, M; Gómez Blanco, N; Llop, J; Mareque-Rivas, JC; Padro, D; Ruiz-de-Angulo, A; Zabaleta, A	1
Chen, Q; Liu, Z; Peng, R; Sun, X; Xu, J; Xu, L; Yang, R; Zhao, Y	1
Chiang, CL; Kandalaft, LE	1
Chen, J; Chen, Q; Han, X; Liang, C; Liu, Z; Xu, J; Xu, L; Yang, Z	1
Allavena, P; Andon, FT; Digifico, E; Maeda, A; Mantovani, A	1
Chen, L; Chen, Y; Guo, L; Liu, C; Ren, W; Sun, L; Xu, H; Yin, H; Yu, L; Yue, W; Zhang, K; Zhang, Y; Zhou, B	1
Hartung, HP; Hofstetter, HH; Kieseier, BC; Mausberg, AK; Weber, A; Zimmermann, C	1
Chang, YN; Cheng, WF; He, L; Huh, W; Hung, CF; Knoff, J; Roden, RB; Song, L; Soong, RS; Trieu, J; Trimble, CL; Tsai, YC; Wu, TC	1
Khaiboullina, SF; Lombardi, VC; Rizvanov, AA	1
Chu, Y; Deng, Y; Huang, E; Jiang, X; Liu, R; Liu, X; Lu, Z; Luo, F; Qian, J; Wang, L; Yang, J; Zhang, D	1
Alignani, D; Guruceaga, E; Hervas-Stubbs, S; Infante, S; Lasarte, JJ; Llopiz, D; Ruiz, M; Sarobe, P; Silva, L; Villanueva, L	1
Gieseler, F; Juricke, M; Kabelitz, D; Kunz, M; Marischen, L; Mundhenke, C; Oberg, HH; Shojaei, H; Wesch, D	1
Glaser, A; Kalb, ML; Koszik, F; Stary, G; Stingl, G	1
Alexopoulou, L; Demaria, O; Desnues, B	1
Boczkowski, D; Dannull, J; Gilboa, E; McLaughlin, C; Nair, S; Su, Z; Vieweg, J; Weizer, A	1
Schön, M; Schön, MP	4
Wooten, JM	1
Chang, YC; Cook-Norris, R; Madkan, V; Sra, K; Tyring, S	1
Marincola, FM; Monsurró, V; Panelli, MC; Wang, E	1
Osterloh, P; Radsak, MP; Rechtsteiner, G; Schild, H; Schmid, B; Warger, T	1
Belardelli, F; Capone, I; Ferrantini, M	1
Alkan, SS; Dumitru, CD; Gibson, SJ; Inglefield, JR; Larson, CJ; Lipson, KE; Tomai, MA; Vasilakos, JP	1
Borden, EC; Grossberg, SE; McAuliffe, TL; Reding, D; Ritch, PS; Westrick, L; Witt, PL	1

Reviews

11 review(s) available for imiquimod and Neoplasms

Article	Year
Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics. Journal of medicinal chemistry, 2023, 05-25, Volume: 66, Issue:10 Topics: Adjuvants, Immunologic; Humans; Imiquimod; Immunity, Innate; Neoplasms; Signal Transduction; Toll-Like Receptors	2023
In vivo cancer vaccination: Which dendritic cells to target and how? Cancer treatment reviews, 2018, Volume: 71 Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Dendritic Cells; Humans; Imiquimod; Immunotherapy; Langerhans Cells; Lectins, C-Type; Membrane Glycoproteins; Molecular Targeted Therapy; Neoplasms; Receptors, Immunologic; Skin; Toll-Like Receptor 3; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptor 9; Toll-Like Receptors	2018
Plasmacytoid dendritic cells, a role in neoplastic prevention and progression. European journal of clinical investigation, 2015, Volume: 45 Suppl 1 Topics: Adjuvants, Immunologic; Aminoquinolines; Cancer Vaccines; Dendritic Cells; Disease Progression; Humans; Imiquimod; Immunotherapy; Melanoma; Neoplasms; Skin Neoplasms; T-Lymphocytes; Toll-Like Receptor 7; Toll-Like Receptors; Tumor Escape; Tumor Microenvironment	2015
Biological Response Modifier in Cancer Immunotherapy. Advances in experimental medicine and biology, 2016, Volume: 909 Topics: Aminoquinolines; Antineoplastic Agents; Clinical Trials as Topic; Gene Expression Regulation, Neoplastic; Humans; Imiquimod; Immunologic Factors; Immunotherapy; Interferon-alpha; Interleukin-2; Mycobacterium bovis; Neoplasms; Receptors, Thrombopoietin; RNA, Untranslated; Signal Transduction; Toll-Like Receptors	2016
Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis : an international journal on programmed cell death, 2004, Volume: 9, Issue:3 Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Basal Cell; Caspases; Cytochrome c Group; Enzyme Activation; Humans; Imiquimod; Melanoma; Mitochondria; Models, Biological; Neoplasms; Ointments; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Vascular Neoplasms	2004
Current and potential uses of imiquimod. Southern medical journal, 2005, Volume: 98, Issue:9 Topics: Adjuvants, Immunologic; Aminoquinolines; Herpes Genitalis; Herpesvirus 2, Human; Humans; Imiquimod; Neoplasms; Skin Diseases; Tattooing	2005
A global approach to tumor immunology. Cellular & molecular immunology, 2004, Volume: 1, Issue:4 Topics: Adjuvants, Immunologic; Aminoquinolines; Cancer Vaccines; Combined Modality Therapy; Gene Expression Profiling; Genomics; Humans; Imiquimod; Immune System; Immunologic Surveillance; Immunotherapy; Inflammation; Interleukin-2; Melanoma; Neoplasms; T-Lymphocytes	2004
The antitumoral mode of action of imiquimod and other imidazoquinolines. Current medicinal chemistry, 2007, Volume: 14, Issue:6 Topics: Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Humans; Imiquimod; Immunity, Cellular; Inflammation; Neoplasms; Quinolines; Toll-Like Receptors	2007
Dendritic cells and cytokines in immune rejection of cancer. Cytokine & growth factor reviews, 2008, Volume: 19, Issue:1 Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antigen Presentation; Antigens, Neoplasm; Cancer Vaccines; Cells, Cultured; Clinical Trials as Topic; CpG Islands; Cytokines; Dendritic Cells; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imiquimod; Immunotherapy; Interferon-alpha; Neoplasms; Oligodeoxyribonucleotides; Toll-Like Receptor 9	2008
Imiquimod: mode of action. The British journal of dermatology, 2007, Volume: 157 Suppl 2 Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Humans; Imiquimod; Immunity, Cellular; Neoplasms; Receptors, Purinergic P1; Signal Transduction; Toll-Like Receptors	2007
TLR7 and TLR8 as targets in cancer therapy. Oncogene, 2008, Jan-07, Volume: 27, Issue:2 Topics: Adjuvants, Immunologic; Aminoquinolines; Antineoplastic Agents; Clinical Trials as Topic; Humans; Imiquimod; Models, Biological; Neoplasms; Toll-Like Receptor 7; Toll-Like Receptor 8; Treatment Outcome	2008

Trials

1 trial(s) available for imiquimod and Neoplasms

Article	Year
Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer research, 1993, Nov-01, Volume: 53, Issue:21 Topics: 2',5'-Oligoadenylate Synthetase; Administration, Oral; Aminoquinolines; Autoantibodies; beta 2-Microglobulin; Biopterins; Drug Administration Schedule; Drug Monitoring; Humans; Imiquimod; Interferon Inducers; Interferon-alpha; Neoplasm Staging; Neoplasms; Neopterin; Tumor Necrosis Factor-alpha	1993

Article

Year

Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.

Cancer research, 1993, Nov-01, Volume: 53, Issue:21

Topics: 2',5'-Oligoadenylate Synthetase; Administration, Oral; Aminoquinolines; Autoantibodies; beta 2-Microglobulin; Biopterins; Drug Administration Schedule; Drug Monitoring; Humans; Imiquimod; Interferon Inducers; Interferon-alpha; Neoplasm Staging; Neoplasms; Neopterin; Tumor Necrosis Factor-alpha

1993

Other Studies

37 other study(ies) available for imiquimod and Neoplasms

Article	Year
Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer. Journal of nanobiotechnology, 2021, Dec-24, Volume: 19, Issue:1 Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Survival; Docetaxel; Ferrocyanides; Humans; Imiquimod; Immunotherapy; Infrared Rays; Macrophages; Mice; Mice, Nude; Nanoparticles; Neoplasms; Optical Imaging; Photothermal Therapy; Polylactic Acid-Polyglycolic Acid Copolymer	2021
The miR-145-MMP1 axis is a critical regulator for imiquimod-induced cancer stemness and chemoresistance. Pharmacological research, 2022, Volume: 179 Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Imiquimod; Matrix Metalloproteinase 1; MicroRNAs; Neoplasms	2022
Light-triggered multifunctional nanoplatform for efficient cancer photo-immunotherapy. Journal of nanobiotechnology, 2022, Apr-07, Volume: 20, Issue:1 Topics: Cell Line, Tumor; Imiquimod; Immunotherapy; Nanoparticles; Neoplasms; Photochemotherapy; Phototherapy; Silicon Dioxide	2022
Enhancement of antitumor immunotherapy using mitochondria-targeted cancer cell membrane-biomimetic MOF-mediated sonodynamic therapy and checkpoint blockade immunotherapy. Journal of nanobiotechnology, 2022, May-14, Volume: 20, Issue:1 Topics: Biomimetics; Cell Line, Tumor; Cell Membrane; Imiquimod; Immune Checkpoint Inhibitors; Immunotherapy; Mitochondria; Neoplasms	2022
Ultrasound improved immune adjuvant delivery to induce DC maturation and T cell activation. Journal of controlled release : official journal of the Controlled Release Society, 2022, Volume: 349 Topics: Adjuvants, Immunologic; CTLA-4 Antigen; Cytokines; Dendritic Cells; Forkhead Transcription Factors; Humans; Imiquimod; Immune Checkpoint Proteins; Immunotherapy; Liposomes; Lymphocyte Activation; Neoplasms; T-Lymphocytes; Toll-Like Receptors	2022
Bidirectional anisotropic palladium nanozymes reprogram macrophages to enhance collaborative chemodynamic therapy of colorectal cancer. Acta biomaterialia, 2022, Oct-01, Volume: 151 Topics: Catalase; Colorectal Neoplasms; Humans; Hyaluronic Acid; Hydrogen Peroxide; Imiquimod; Macrophages; Mannose; Neoplasms; Oxygen; Palladium; Reactive Oxygen Species; Tumor Microenvironment	2022
Targeted delivery of liposomal chemoimmunotherapy for cancer treatment. Frontiers in immunology, 2022, Volume: 13 Topics: Cell Line, Tumor; Doxorubicin; Imiquimod; Immunologic Factors; Immunotherapy; Liposomes; Neoplasms	2022
Nanoscale Hafnium Metal-Organic Frameworks Enhance Radiotherapeutic Effects by Upregulation of Type I Interferon and TLR7 Expression. Advanced healthcare materials, 2023, Volume: 12, Issue:13 Topics: Cell Line, Tumor; Hafnium; Humans; Imiquimod; Interferon Type I; Metal-Organic Frameworks; Neoplasms; Toll-Like Receptor 7; Up-Regulation	2023
Bioorthogonal-Activated In Situ Vaccine Mediated by a COF-Based Catalytic Platform for Potent Cancer Immunotherapy. Journal of the American Chemical Society, 2023, 03-08, Volume: 145, Issue:9 Topics: Adjuvants, Immunologic; Cancer Vaccines; Cell Line, Tumor; Doxorubicin; Humans; Imiquimod; Immunotherapy; Metal-Organic Frameworks; Neoplasms	2023
Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer. Molecules (Basel, Switzerland), 2023, Mar-31, Volume: 28, Issue:7 Topics: Adjuvants, Immunologic; CD47 Antigen; Colonic Neoplasms; Humans; Imiquimod; Immunotherapy; Liposomes; Neoplasms; Toll-Like Receptor 7	2023
Molecular Engineering of NIR-II/IIb Emitting AIEgen for Multimodal Imaging-Guided Photo-Immunotherapy. Small (Weinheim an der Bergstrasse, Germany), 2023, Volume: 19, Issue:32 Topics: Cell Line, Tumor; Humans; Imiquimod; Immunotherapy; Multimodal Imaging; Nanoparticles; Neoplasms; Optical Imaging; Phototherapy	2023
Analgesic and potentiated photothermal therapy with ropivacaine-loaded hydrogels. Theranostics, 2023, Volume: 13, Issue:7 Topics: Analgesics; Animals; CD8-Positive T-Lymphocytes; Hydrogels; Imiquimod; Indocyanine Green; Mice; Neoplasms; Pain; Phototherapy; Photothermal Therapy; Ropivacaine	2023
NIR-II imaging-guided photothermal cancer therapy combined with enhanced immunogenic death. Biomaterials science, 2023, Jul-25, Volume: 11, Issue:15 Topics: Cell Line, Tumor; Diagnostic Imaging; Humans; Imiquimod; Nanoparticles; Neoplasms; Phototherapy; Photothermal Therapy; Tumor Microenvironment	2023
Immunological gadolinium-doped mesoporous carbon nanoparticles for tumor-targeted MRI and photothermal-immune co-therapy. Journal of materials chemistry. B, 2023, 07-05, Volume: 11, Issue:26 Topics: Carbon; Gadolinium; Humans; Imiquimod; Magnetic Resonance Imaging; Nanoparticles; Neoplasms; Phototherapy; Photothermal Therapy	2023
The dynamic therapeutic effect of a targeted photothermal nanovaccine incorporating toll-like receptor 7 agonist enhanced cancer immunotherapy. Journal of materials chemistry. B, 2023, 09-27, Volume: 11, Issue:37 Topics: Adjuvants, Immunologic; Cell Differentiation; Imiquimod; Immunotherapy; Neoplasms; Toll-Like Receptor 7	2023
Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection. Frontiers in immunology, 2023, Volume: 14 Topics: Adjuvants, Immunologic; Animals; Anthralin; CD8-Positive T-Lymphocytes; Dermatitis; Humans; Imiquimod; Immunization; Mice; Mice, Inbred C57BL; Neoplasms; Vaccination	2023
Modular Engineering of Targeted Dual-Drug Nanoassemblies for Cancer Chemoimmunotherapy. ACS applied materials & interfaces, 2019, Oct-09, Volume: 11, Issue:40 Topics: Animals; Antigen Presentation; Apoptosis; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Drug Therapy; Female; Imiquimod; Immunotherapy; Mice, Inbred BALB C; Nanoparticles; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Rats, Sprague-Dawley; Tissue Distribution	2019
Diet-induced obesity exacerbates imiquimod-mediated psoriasiform dermatitis in anti-PD-1 antibody-treated mice: Implications for patients being treated with checkpoint inhibitors for cancer. Journal of dermatological science, 2020, Volume: 97, Issue:3 Topics: Animals; Diet, Western; Disease Models, Animal; Female; Humans; Imiquimod; Immune Checkpoint Inhibitors; Mice; Neoplasms; Obesity; Programmed Cell Death 1 Receptor; Psoriasis; Risk Factors; Skin; Symptom Flare Up	2020
Biodegradable pH-responsive amorphous calcium carbonate nanoparticles as immunoadjuvants for multimodal imaging and enhanced photoimmunotherapy. Journal of materials chemistry. B, 2020, 09-23, Volume: 8, Issue:36 Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Calcium Carbonate; Cell Line, Tumor; Contrast Media; Female; Hydrogen-Ion Concentration; Imiquimod; Immunotherapy; Indocyanine Green; Infrared Rays; Manganese; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Photosensitizing Agents; Theranostic Nanomedicine; Tumor Microenvironment	2020
Imiquimod does not elicit inflammatory responses in the skin of the naked mole rat (Heterocephalus glaber). BMC research notes, 2020, Sep-05, Volume: 13, Issue:1 Topics: Animals; Imiquimod; Longevity; Mole Rats; Neoplasms; Skin	2020
CD4 Cancer immunology research, 2017, Volume: 5, Issue:8 Topics: Aminoquinolines; Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemokine CXCL10; Chemokine CXCL9; Humans; Imiquimod; Killer Cells, Natural; Lymphocyte Activation; Major Histocompatibility Complex; Membrane Glycoproteins; Mice; Neoplasms; Receptors, CXCR3; Toll-Like Receptor 3; Toll-Like Receptor 7; Toll-Like Receptor 9; Tumor Microenvironment	2017
Inflammatory memory sensitizes skin epithelial stem cells to tissue damage. Nature, 2017, 10-26, Volume: 550, Issue:7677 Topics: Aminoquinolines; Animals; Autoimmune Diseases; Caspase 1; Cell Lineage; Chromatin; DNA-Binding Proteins; Epigenesis, Genetic; Epithelial Cells; Female; Imiquimod; Inflammasomes; Inflammation; Interleukin-1beta; Macrophages; Mice; Neoplasms; Regeneration; Skin; Stem Cells; Stress, Physiological; T-Lymphocytes; Wound Healing	2017
Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles. Biomaterials, 2018, Volume: 170 Topics: Animals; Antigen-Presenting Cells; Cancer Vaccines; Cell Death; Cell Line; Cell Line, Tumor; Cell Movement; Drug Synergism; Endocytosis; Endosomes; Imiquimod; Immunity, Innate; Immunization; Immunotherapy; Lymph Nodes; Magnetite Nanoparticles; Melanoma; Mice, Inbred C57BL; Nanotechnology; Neoplasms; Phospholipids; Poly I-C; Polyethylene Glycols	2018
Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination. ACS nano, 2018, 06-26, Volume: 12, Issue:6 Topics: Animals; Antigens, Neoplasm; Cancer Vaccines; Cell Line, Tumor; Cell Membrane; Female; Imiquimod; Immunotherapy; Mannose; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Optical Imaging; Polylactic Acid-Polyglycolic Acid Copolymer	2018
Nanoparticle-Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy. Advanced materials (Deerfield Beach, Fla.), 2019, Volume: 31, Issue:10 Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Humans; Imiquimod; Immunotherapy; Mice; Nanoparticles; Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer; Radiotherapy	2019
Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages. European journal of immunology, 2019, Volume: 49, Issue:5 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cytokines; Humans; Imiquimod; Immunomodulation; Macrophages; Neoplasms; Poly I-C; Tumor Microenvironment	2019
Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. Nature communications, 2019, 05-02, Volume: 10, Issue:1 Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Immunological; Apoptosis; B7-H1 Antigen; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Hematoporphyrins; Humans; Imiquimod; Immunotherapy; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Neoplasms; Treatment Outcome; Ultrasonic Therapy	2019
Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod™. International immunopharmacology, 2013, Volume: 17, Issue:2 Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; Cells, Cultured; Drug Synergism; Female; Imidazoles; Imiquimod; Infections; Inflammation Mediators; Interferon-gamma; Interleukin-6; Mice; Mice, Inbred C57BL; Neoplasms; Thymocytes	2013
Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Nov-01, Volume: 20, Issue:21 Topics: Aminoquinolines; Animals; Antigens; CD8-Positive T-Lymphocytes; Female; Genitalia; Imiquimod; Integrin alpha1; Interferon gamma Receptor; Interferon-gamma; Mice; Mice, Inbred C57BL; Neoplasms; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Papillomavirus Vaccines; Receptors, Interferon; Repressor Proteins; Toll-Like Receptors; Vaccination; Vaccines, DNA	2014
IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. Oncotarget, 2017, Jan-10, Volume: 8, Issue:2 Topics: Aminoquinolines; Animals; B7-H1 Antigen; Cancer Vaccines; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Female; Humans; Imiquimod; Immunomodulation; Immunophenotyping; Immunotherapy; Interleukin-10; Lymphocyte Activation; Melanoma, Experimental; Mice; Mice, Transgenic; Neoplasms; Phenotype; T-Lymphocytes; Vaccination; Xenograft Model Antitumor Assays	2017
Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer research, 2009, Nov-15, Volume: 69, Issue:22 Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Cytotoxicity, Immunologic; Flow Cytometry; Histocompatibility Antigens Class I; Humans; Imiquimod; Neoplasms; Poly I-C; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; T-Lymphocytes; Toll-Like Receptor 3; Toll-Like Receptor 7	2009
TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity. Journal of immunology (Baltimore, Md. : 1950), 2012, Feb-15, Volume: 188, Issue:4 Topics: Aminoquinolines; Cell Line, Tumor; Dendritic Cells; Humans; Imiquimod; Interferon Inducers; Interferon-alpha; Jurkat Cells; Melanoma; Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptor 9	2012
[Toll-like receptor 8: the awkward TLR]. Medecine sciences : M/S, 2012, Volume: 28, Issue:1 Topics: Adaptive Immunity; Aminoquinolines; Animals; Autoimmune Diseases; Clinical Trials, Phase I as Topic; Cytokines; Drug Evaluation, Preclinical; Gene Expression Regulation; Imiquimod; Immunity, Innate; Ligands; Lupus Erythematosus, Systemic; Membrane Glycoproteins; Mice; Models, Immunological; Neoplasms; RNA, Viral; Signal Transduction; Species Specificity; Toll-Like Receptor 3; Toll-Like Receptor 7; Toll-Like Receptor 8; Virus Diseases	2012
Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. Journal of immunology (Baltimore, Md. : 1950), 2003, Dec-01, Volume: 171, Issue:11 Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cells, Cultured; Dendritic Cells; Humans; Imiquimod; Injections, Subcutaneous; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasms; Skin; Species Specificity; Stem Cells	2003
Imiquimod. Southern medical journal, 2005, Volume: 98, Issue:9 Topics: Adjuvants, Immunologic; Aminoquinolines; Cytokines; Humans; Imiquimod; Neoplasms; Skin Diseases	2005
Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clinical reviews in allergy & immunology, 2007, Volume: 32, Issue:1 Topics: Administration, Cutaneous; Aminoquinolines; Animals; CD40 Antigens; Cell Line, Tumor; Imiquimod; Immunization; Immunologic Memory; Immunotherapy; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms; Survival Rate; T-Lymphocytes, Cytotoxic; Time Factors	2007
TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2008, Volume: 28, Issue:4 Topics: Aminoquinolines; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Dendritic Cells; Humans; Imiquimod; Interferon Type I; Leukocytes, Mononuclear; Lung; Melanoma; Mice; Neoplasms; Oligodeoxyribonucleotides; Quinolines; Subcellular Fractions; Sulfonamides; Toll-Like Receptor 7; Toll-Like Receptor 9	2008